Pharming Group NV lost nearly 25 percent of its value March 20 on news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) was standing by its original decision to adopt a negative opinion on an application for its hereditary angioedema (HAE) drug Rhucin. (BioWorld International)

Basilea Pharmaceutica AG took a heavy pounding on the Swiss Stock Exchange in Zurich Tuesday, on news that the company had received an approvable letter from the FDA in response to its new drug application filing for the cephalosporin antibiotic ceftobiprole. (BioWorld International)